We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Leti Startup to Provide Improved Cancer Surgery

Leti Startup to Provide Improved Cancer Surgery

Leti Startup to Provide Improved Cancer Surgery

Leti Startup to Provide Improved Cancer Surgery

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Leti Startup to Provide Improved Cancer Surgery"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Leti has announced that it has launched a new company, Fluoptics that is expected to improve surgery of some types of cancers.

Combining technologies developed by Leti and Université Joseph Fourier in Grenoble, Fluoptics developed an innovative approach of fluorescence imaging for cancer targeting. This new real-time, imaging technique improves detection of tumors and helps surgeons to delineate it for exerese.

Fluoptics, the 30th startup launched by Leti, expects to commercialize its FluoBeam instrument in 2010 for pre-clinical research and begin regulatory the toxicity phases of its first fluorescent marker.

“Fluoptics not only exemplifies Leti’s mission of creating innovation and transferring it to industry, but it also is our first startup in the growing field of bio-medicine,” said Laurent Malier, CEO of Leti. “The company has great potential to improve the detection and treatment of cancer, and to have a real impact on the lives of cancer patients.”

“It is very difficult to distinguish between cancerous and healthy tissue, and our technology is the only intra-operative technique available to help surgeons precisely locate and delineate tumors,” said Odile Allard, CEO of Fluoptics. “Our incubation in Leti enabled the finalization of the laboratory prototype and its preclinical validation by surgeons specialized in cancer.”

Fluoptics, one of the four startups launched by Leti in the past year, will be based in MINATEC.